Catalyst Pharmaceuticals, Inc.

CPRX

US14888U1016

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:09:33 17/07/2024 pm IST			5-day change	1st Jan Change
16.86 ^USD	-0.77%		+9.38%	+0.59%

05/06	Catalyst Pharmaceuticals Insider Sold Shares Worth $276,735, According to a Recent SEC Filing	MT
30/05	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

Catalyst Pharmaceuticals, Inc Provides Net Product Revenues Guidance for the Full Year 2020

January 06, 2020 at 07:26 pm IST

Catalyst Pharmaceuticals, Inc. provided net product revenues guidance for the full year 2020. For the year, the company expected net product revenues for treating adult LEMS patients to be in the range of $135 to $155 million.

Latest news about Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Insider Sold Shares Worth $276,735, According to a Recent SEC Filing	06/06	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	31/05	MT
Catalyst Pharmaceuticals Gets FDA Approval for Dose Increase in LEMS Drug	30/05	MT
Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE	30/05	CI
Transcript : Catalyst Pharmaceuticals, Inc. - Shareholder/Analyst Call	21/05
Transcript : Catalyst Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 05:01 PM	15/05
HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating	10/05	MT
Transcript : Catalyst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Posts Q1 EPS $0.38, vs. Street Est of $0.30	09/05	MT
Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024	09/05	CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	11/04	MT
Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04	CI
Certain Restricted Stock Units of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04	CI
Certain Common Stock of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04	CI
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing	29/03	MT
Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target	14/03	MT
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States	14/03	DJ
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy	13/03	MT
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy	13/03	CI
Transcript : Catalyst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM	12/03
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals	07/03	MT
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23	07/03	MT
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating	01/03	MT
Transcript : Catalyst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 29, 2024	29/02

Chart Catalyst Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Catalyst Pharmaceuticals, Inc: Optimistic scenario

March 06, 2023 at 09:14 pm IST

More Strategies

Ratings for Catalyst Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.99 USD

Average target price

27.29 USD

Spread / Average Target

+60.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CATALYST PHARMACEUTICALS, INC.	+0.59%	2.01B
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	42.34B
BIOGEN INC.	-12.12%	32.76B
UCB	+79.34%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-12.28%	16.31B
INCYTE CORPORATION	+2.39%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.23B
ALTEOGEN INC.	+178.17%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	+1.50%	8.97B

Biopharmaceuticals